Novo Nordisk reported a 13% rise in sales in the first quarter of 2013 to DKK 20 billion (€2.7 billion) and an 18% increase in operating profit to DKK 7.6 billion as a result of continuing strong sales of diabetes products in the US. ---Subscribe to MedNous to access this article--- Company News
